Format

Send to

Choose Destination
J Heart Lung Transplant. 2014 Apr;33(4):438-45. doi: 10.1016/j.healun.2013.12.004. Epub 2013 Dec 17.

An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure.

Author information

1
Cardiology and Medicine, Southern Arizona VA Health Care System; Sarver Heart Center; Department of Physiology. Electronic address: jordan.lancaster@va.gov.
2
Cardiology and Medicine, Southern Arizona VA Health Care System; Sarver Heart Center.
3
Medical Imaging, University of Arizona, Tucson.
4
Northern Arizona University, Flagstaff.
5
Department of Physiology.
6
Banner Sun Health Research Institute, Sun City, Arizona.

Abstract

BACKGROUND:

Varying strategies are currently being evaluated to develop tissue-engineered constructs for the treatment of ischemic heart disease. This study examines an angiogenic and biodegradable cardiac construct seeded with neonatal cardiomyocytes for the treatment of chronic heart failure (CHF).

METHODS:

We evaluated a neonatal cardiomyocyte (NCM)-seeded 3-dimensional fibroblast construct (3DFC) in vitro for the presence of functional gap junctions and the potential of the NCM-3DFC to restore left ventricular (LV) function in an in vivo rat model of CHF at 3 weeks after permanent left coronary artery ligation.

RESULTS:

The NCM-3DFC demonstrated extensive cell-to-cell connectivity after dye injection. At 5 days in culture, the patch contracted spontaneously in a rhythmic and directional fashion at 43 ± 3 beats/min, with a mean displacement of 1.3 ± 0.3 mm and contraction velocity of 0.8 ± 0.2 mm/sec. The seeded patch could be electrically paced at nearly physiologic rates (270 ± 30 beats/min) while maintaining coordinated, directional contractions. Three weeks after implantation, the NCM-3DFC improved LV function by increasing (p < 0.05) ejection fraction 26%, cardiac index 33%, dP/dt(+) 25%, dP/dt(-) 23%, and peak developed pressure 30%, while decreasing (p < 0.05) LV end diastolic pressure 38% and the time constant of relaxation (Tau) 16%. At 18 weeks after implantation, the NCM-3DFC improved LV function by increasing (p < 0.05) ejection fraction 54%, mean arterial pressure 20%, dP/dt(+) 16%, dP/dt(-) 34%, and peak developed pressure 39%.

CONCLUSIONS:

This study demonstrates that a multicellular, electromechanically organized cardiomyocyte scaffold, constructed in vitro by seeding NCM onto 3DFC, can improve LV function long-term when implanted in rats with CHF.

KEYWORDS:

cardiomyocytes; cell therapy; chronic heart failure; ejection fraction; ventricles; ventricular function

PMID:
24560982
PMCID:
PMC3966928
DOI:
10.1016/j.healun.2013.12.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center